Crescita Therapeutics Valuation
| CRRTF Stock | USD 0.45 0.00 0.00% |
Crescita Therapeutics is overvalued. Crescita Therapeutics shows a prevailing Real Value of $0.29 per share. The current price of the firm is $0.45. Our model approximates the value of Crescita Therapeutics from analyzing the firm fundamentals such as return on equity of 0.0318, and Profit Margin of 0.03 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Crescita Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Crescita Therapeutics is based on 3 months time horizon. Increasing Crescita Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Crescita pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Crescita Therapeutics. Since Crescita Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Crescita Pink Sheet. However, Crescita Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.45 | Real 0.29 | Hype 0.45 | Naive 0.52 |
The real value of Crescita Pink Sheet, also known as its intrinsic value, is the underlying worth of Crescita Therapeutics Company, which is reflected in its stock price. It is based on Crescita Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Crescita Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Crescita Therapeutics helps investors to forecast how Crescita pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Crescita Therapeutics more accurately as focusing exclusively on Crescita Therapeutics' fundamentals will not take into account other important factors: Crescita Therapeutics Total Value Analysis
Crescita Therapeutics is currently anticipated to have takeover price of 3.64 M with market capitalization of 11.42 M, debt of 1.71 M, and cash on hands of 10.5 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Crescita Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.64 M | 11.42 M | 1.71 M | 10.5 M |
Crescita Therapeutics Investor Information
The company has price-to-book (P/B) ratio of 0.66. Some equities with similar Price to Book (P/B) outperform the market in the long run. Crescita Therapeutics has Price/Earnings (P/E) ratio of 490.0. The entity had not issued any dividends in recent years. Based on the key indicators related to Crescita Therapeutics' liquidity, profitability, solvency, and operating efficiency, Crescita Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Crescita Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Crescita Therapeutics has an asset utilization ratio of 57.98 percent. This implies that the Company is making $0.58 for each dollar of assets. An increasing asset utilization means that Crescita Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Crescita Therapeutics Ownership Allocation
Crescita Therapeutics holds a total of 20.4 Million outstanding shares. Crescita Therapeutics shows 7.3 percent of its outstanding shares held by insiders and 0.0 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Crescita Therapeutics Profitability Analysis
The company reported the revenue of 16.77 M. Net Loss for the year was (1.1 M) with profit before overhead, payroll, taxes, and interest of 10.01 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Crescita Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Crescita Therapeutics and how it compares across the competition.
About Crescita Therapeutics Valuation
The pink sheet valuation mechanism determines Crescita Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Crescita Therapeutics. We calculate exposure to Crescita Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Crescita Therapeutics's related companies.Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada. Crescita Therapeutics is traded on OTC Exchange in the United States.
8 Steps to conduct Crescita Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Crescita Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Crescita Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Crescita Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Crescita Therapeutics' revenue streams: Identify Crescita Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Crescita Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Crescita Therapeutics' growth potential: Evaluate Crescita Therapeutics' management, business model, and growth potential.
- Determine Crescita Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Crescita Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Crescita Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Crescita Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 21 M | |
| Quarterly Earnings Growth Y O Y | 45.163 | |
| Retained Earnings | -41.5 M |
Complementary Tools for Crescita Pink Sheet analysis
When running Crescita Therapeutics' price analysis, check to measure Crescita Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crescita Therapeutics is operating at the current time. Most of Crescita Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crescita Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crescita Therapeutics' price. Additionally, you may evaluate how the addition of Crescita Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Transaction History View history of all your transactions and understand their impact on performance |